已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Trial of Irreversible KRASG12C Inhibitor AMG 510 Reveals Clinical Activity

作者
Richard Simoneaux
出处
期刊:Oncology times [Wolters Kluwer]
卷期号:41 (21): 33-33 被引量:1
标识
DOI:10.1097/01.cot.0000612764.66084.52
摘要

BARCELONA—Mutations to the proto-oncogene KRAS are drivers in a number of malignancies. The KRASG12C mutation, in which the glycine present as the 12th residue in the wild-type protein is replaced by a cysteine, is present in roughly 13 percent of lung cancers, 3 percent of colorectal cancers, and 1-3 percent of other solid cancers. AMG 510 is a first-in-class selective irreversible KRASG12C inhibitor that is currently being evaluated in a first-in-human phase I/II study (NCT03600883) in patients with malignancies that have been confirmed to have KRASG12C-mutant disease. Results from this study were recently presented at the 2019 World Conference on Lung Cancer (WCLC) by Ramaswamy Govindan, MD, Professor of Medicine; Anheuser Busch Chair in Medical Oncology; Director, Section of Medical Oncology, Division of Oncology, Washington University School of Medicine, St. Louis, Mo. “Historically, it was thought that KRAS was an ‘undruggable’ target, however, in this study, we did see some clinical activity, with partial responses achieved in seven out of 13 evaluable patients (two confirmed as of cutoff) with an objective response rate (ORR) of 54 percent in previously treated patients with non-small cell lung cancer (NSCLC). “In addition, the investigational compound appears to show good selectivity for the KRASG12C mutant, as there were no serious or fatal treatment-associated adverse events (AEs); if broad-based binding to multiple Ras isoforms was occurring, one would expect to see serious toxicities.” In September 2019, the FDA granted Fast Track designation to AMG 510 for the treatment of adults with KRASG12C-mutant NSCLC who had received prior treatment. AMG 510 is an irreversible inhibitor of the mutant KRASG12C protein. Mechanistically, it undergoes a rapid reaction and forms a covalent bond with the thiol moiety of the cysteine-12 residue of guanosine diphosphate (GDP)-bound KRASG12C (ACS Med Chem Lett 2019;10(9):1302-1308). “In doing so,” Govindan explained, “the protein is locked in an inactive, GDP-bound state.” When asked if this compound inhibited normal, wild-type (WT) KRAS, he noted, “Because the compound forms a covalent bond with the cysteine present in the mutant protein, this inhibitor displays remarkable selectivity, with no inhibition of the WT KRAS.” Study Details The primary objectives of this clinical trial are to assess safety and tolerability of AMG 510 in adult patients having KRASG12C-mutant solid tumor malignancies. An additional objective in this trial is the assessment of dose-limiting toxicities to determine the maximum tolerated dose and/or the recommended phase II dose in these same patients. Key secondary study endpoints included the following: pharmacokinetic assessment, ORR, disease control rate (DCR), progression-free survival, duration of response, and duration of stable disease. Among the key inclusion criteria were locally advanced or metastatic, molecularly confirmed KRASG12C-mutant solid tumor malignancy, prior treatment with standard therapies, and no active brain/CNS metastases. The phase I portion of the trial is an open-label, multicenter dose-escalation study. The phase II portion of the study is an expansion phase and uses the recommended phase II dose determined in the dose escalation part of the trial. Results First patient enrollment occurred on Aug. 27, 2018, while the date for data cutoff was July 17, 2019. The analyses presented by Govindan at WCLC included results from the 34 patients with NSCLC. Of these patients, 19 were included in the dose-escalation cohort at the following levels: 180 mg (3), 360 mg (2), 720 mg (6), and 960 mg (8). A total of 15 patients were included in the expansion cohort which was dosed at 960 mg/day. There was a total of 23 patients who were evaluable who had the first 6-week scan or early disease progression; of these, 13 received the recommended phase II dosage of 960 mg/day. No dose-limiting toxicities were observed in the safety population of 34 patients. A total of 12 patients in this population experienced a treatment-related AE; however, the majority were minor (grade 1 or 2). There were only three incidents of grade 3 AEs (diarrhea–2 and anemia–1). Pharmacokinetics analyses showed a maximum serum concentration (Cmax) of 7.5 μg/mL and an AUC (area under the time-concentration curve) of 65.3 hr∗μg/mL. In addition, these analyses afforded a mean elimination half-life (t½) of 5.5 hours. Among the 23 evaluable patients, 11 showed a partial response, 11 showed stable disease, while one showed progressive disease. These figures gave an ORR of 48 percent and a DCR of 96 percent. Among the 13 evaluable patients at the recommended phase II dosage of 960 mg/day, seven showed a partial response while six showed stable disease for an ORR and DCR of 54 percent and 100 percent, respectively. Among the 11 patients that showed a partial response to therapy with AMG 510, the median duration of treatment was 15.1 weeks with a range of 4.1 to 42.3 weeks. Discussion When asked what he thought the major lesson was from this study, Govindan replied, “For the first time in humans, we have used AMG 510 against a target that was previously thought to be ‘undruggable’; moreover, there was some efficacy in previously treated NSCLC patients with metastatic or locally advanced KRASG12C-mutant disease, as shown by the ORR of 54 percent and DCR of 100 percent in those evaluable patients receiving the recommended phase II dosage. “AMG 510 displayed a favorable safety profile at all dose levels tested; importantly, no dose-limiting toxicities have been observed. In addition, no cumulative toxicities were noted, even with extended treatment.” When discussing the next steps for AMG 510, Govindan stated, “Currently, enrollment is ongoing for phase I studies evaluating AMG 510 in combinations with other drugs, as well as phase II monotherapy studies.” Richard Simoneaux is a contributing writer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
共享精神的应助被认真的莹采纳,获得10
1秒前
科目三的应助被霸气茗采纳,获得10
2秒前
高贵的滑板完成签到 ,获得积分10
2秒前
王一生完成签到,获得积分0
3秒前
3秒前
Akim的应助被爱you采纳,获得10
4秒前
5秒前
陈住气完成签到,获得积分10
5秒前
我是老大的应助被啦啦啦采纳,获得10
6秒前
大胆路人完成签到 ,获得积分10
6秒前
xuan完成签到 ,获得积分10
6秒前
7秒前
拾光&完成签到 ,获得积分10
7秒前
小蘑菇的应助被淡然冬灵采纳,获得10
7秒前
Hongtao完成签到 ,获得积分10
7秒前
lll完成签到,获得积分10
7秒前
粥仙僧发布了新的文献求助30
8秒前
Ava的应助被123采纳,获得10
8秒前
8秒前
9秒前
shelly发布了新的文献求助10
9秒前
11秒前
笑点低忆之完成签到 ,获得积分10
11秒前
12秒前
顺利的楷瑞完成签到 ,获得积分10
12秒前
12秒前
挚友发布了新的文献求助10
13秒前
布布的应助被健壮的傲之采纳,获得10
13秒前
香锅完成签到,获得积分10
13秒前
认真的莹发布了新的文献求助10
14秒前
健壮绮彤关注了科研通微信公众号
15秒前
16秒前
一丁雨发布了新的文献求助10
17秒前
五嶽完成签到 ,获得积分10
17秒前
19秒前
温暖忆山的应助被雷霆大土豆采纳,获得10
19秒前
Owen的应助被啦啦啦采纳,获得10
19秒前
20秒前
情怀的应助被coco采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194689
求助须知:如何正确求助?哪些是违规求助? 9580456
关于积分的说明 21871058
捐赠科研通 7794234
什么是DOI,文献DOI怎么找? 3437711
关于科研通互助平台的介绍 2561001
邀请新用户注册赠送积分活动 2484417